Top 25 global biotech companies in 2019: 5 Chinese companies including Hengrui and Wuxi pharmaceutical

Compile newborn Recently, foreign biotechnology website Gen released the list of top 25 biotechnology companies of 2019 The list is based on the market value as of October 30, 2019, and the data comes from major stock exchanges or other publicly available resources Amgen ranked first with a market value of $126.5 billion, Novo Nordisk ranked second with a market value of $103.5 billion, ranking one place higher than last year, and CSL ranked third with a market value of $80.3 billion, ranking two places higher than last year Gilead science dropped out of the top three, ranking fourth with a market value of $80 billion Bojian, a biotech company worthy of special mention in this year's list, ranked fourth last year with us $61.479 billion, but its market value has plummeted since the two phase III clinical failures of the Alzheimer's monoclonal antibody, aducanumab On October 22 this year, Bojian announced that it plans to submit the listing application of aducanumab to the US FDA in early 2020 After that, the stock price rose 40% before the opening of the day and 26% on the closing day In the seven trading days after Bojian's share price soared, most biotechnology stocks also rose In this year's list, the company ranked eighth with $54.1 billion, still down 12.0% from the same period last year In this year's list, there are five Chinese biotechnology companies listed, respectively: Hengrui Pharmaceutical (market value: 398.8 billion yuan, ranking 7th) Wuxi apptec (market value: 133.5 billion yuan, ranking 14th) Hausen Pharmaceutical (HK $139.5 billion, 16th) Yunnan Baiyao (market value: 107.3 billion yuan, ranking 19th) Sinopharm group (market value: HK $82.8 billion, ranking 24) In addition, South Korea, Belgium and Denmark have two biotechnology companies on the list Australia, India and Ireland have one company on the list Of the 25 companies on the list, more than half are outside the United States In terms of market value, the total market value of 25 companies in this year's list is US $963.67 billion, an increase of 4.9% compared with last year, which is the first increase since the total market value of the companies in this list has continuously declined (US $1047 billion in 2016, US $1007 billion in 2017 and US $918.85 billion in 2018) after reaching the highest level in 2015 (US $1225 billion) Of the 25 companies on the list this year, 12 have seen their market value increase and 12 have seen their market value shrink; Howson pharmaceutical was not listed last year, so it can't be compared Mylan, the 25th company on the list this year, has a market value of $10 billion, compared with Perrigo, the lowest ranked company last year, with a market value of $9.4 billion Alnylam pharmaceuticals, the No 26 company, had a market capitalization of just over $9.7 billion on October 30, followed by neurocrine (US $8.974 billion) and TIWA pharmaceuticals Among them, TIWA pharmaceutical ranked 15th on the list with a market value of US $20.4 billion last year, but due to the huge impact of generic drugs, the market value of the company had dropped 57.8% to US $8.635 billion as of October 30 this year The specific list is as follows: